Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

How a Drug Company Made $114 Billion by Gaming the U.S. Patent System

The New York Times – Business:

AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end.

Rebecca Robbins
Author: Rebecca Robbins

This post first appeared in The New York Times – Business. Read the original article.

Written by

Rebecca Robbins

in

Antitrust Laws and Competition Issues, Drugs (Pharmaceuticals), Humira (Drug), Intellectual Property, Inventions and Patents, Prices (Fares, Fees and Rates), Suits and Litigation (Civil)
←When Private Equity Came for the Toddler Gyms
How a Football Superfan in a Wolf Costume Ended Up in a Cage→

More posts

  • ‘Artificial’s Ike Barinholtz Teases What Makes His “Menacing” Elon Musk Performance “A Little Ridiculous”

  • Kelly Clarkson says a Brooklyn store snubbed her. The shop says the item she wanted wasn’t for sale.

  • Idaho College Murder Victims Honored at Friends’ Wedding Who Found Their Bodies

  • Robert Pattinson Approached Chris Hansen Portrayal In ‘Primetime’ As “A Fan”: “I Was Trying To Make Him Cool”

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube